Gorilla Glue Cannabis Extracts: Cannabinoid Profiling and CBD Hydrolysis Investigation
DOI:
https://doi.org/10.48797/sl.2026.495Keywords:
Poster CommunicationAbstract
Background: Medicinal plants are a significant source of bioactive compounds with pharmacological relevance, leading to increased interest in species such as Cannabis sativa L. This plant is particularly rich in cannabinoids, a class of biologically active compounds with potential therapeutic benefits. To date, more than one hundred cannabinoids have been identified; however, only a few, such as cannabidiol (CBD), have been the focus of extensive research [1]. In fact, Epidiolex® is an oral solution that contains 100 mg of CBD per 1 mL and has already been approved for the treatment of epilepsy symptoms [2]. The decarboxylated Gorilla Glue (GG) cultivar extract used in this study was chosen for its high CBD content. A decarboxylation step was essential for converting cannabidiolic acid (CBDA) present in the flower into its biologically active neutral form, CBD. This cannabinoid is the most commonly found in cannabis-related products; consequently, it has the potential to become an environmental contaminant, highlighting the critical need to assess its stability in different conditions. Objective: This study aims to evaluate the cannabinoid profile of decarboxylated GG extract and the stability of CBD within the extract under different pH conditions (4, 7, and 9) at 50 ºC over a 9-day period. Methods: Cannabis flowers were finely ground using a mixer mill (Retsch MM400) equipped with stainless steel grinding balls. The decarboxylation step was carried out in an oven at 130 °C for 2 h. Finally, dynamic maceration extraction was conducted in the same ball mill using 96% (v/v) ethanol for 10 minutes. The resulting extracts were filtered, diluted, and analyzed by high-performance liquid chromatography (HPLC) using an Agilent 1260 Infinity II system equipped with an InfinityLab Poroshell 120 EC-C18 column [3]. Hydrolysis assays were then conducted by incubating the extract under sterile conditions at different pH levels. Results: The cannabinoid profile of the GG decarboxylated extract, expressed as % (w/w), was found to be: 49.34% CBD, 2.43% CBC, 1.82% Δ9-THC, 0.89% CBDA, and 0.35% CBN. After nine days under hydrolysis conditions, CBD remained present at 81%, 60%, and 61% at pH levels of 4, 7, and 9, respectively. Conclusions: CBD constitutes 49.34% of the decarboxylated GG extracts, and preliminary hydrolysis studies indicated that it is more stable under acidic conditions.
References
1.Silva, E.M.P. et al. Recent HPLC-UV Approaches for Cannabinoid Analysis: From Extraction to Method Validation and Quantification Compliance. Pharmaceuticals 2025, 18, 786-786, doi:10.3390/ph18060786.
2.Wechsler, R.T. et al. Consensus Panel Recommendations for the Optimization of EPIDIOLEX® Treatment for Seizures Associated with Lennox-Gastaut Syndrome, Dravet Syndrome, and Tuberous Sclerosis Complex. Epilepsia Open. 2024, 5, 1632-1642, doi: 10.1002/epi4.12956.
3.Morais, A.F. et al. Optimization and Validation of an HPLC-DAD Method for the Identification of 14 Cannabinoids: Application in Cannabis sativa L Extracts. Sci Lett, 2025 1 (Sup 1), doi: 10.48797/sl.2025.319.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Virginie Mariottini , Eduarda M. P. Silva , Carlos J. A. Ribeiro, Alexandra S. Maia

This work is licensed under a Creative Commons Attribution 4.0 International License.
In Scientific Letters, articles are published under a CC-BY license (Creative Commons Attribution 4.0 International License), the most open license available. The users can share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as they give appropriate credit, provide a link to the license, and indicate if changes were made (read the full text of the license terms and conditions of use).
The author is the owner of the copyright.






